Literature DB >> 23369532

A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis.

Susana Borges1, Charlotte Gayer-Anderson, Valeria Mondelli.   

Abstract

Up to now studies on hypothalamic-pituitary-adrenal (HPA) axis activity in psychosis have shown inconsistent findings. These inconsistencies have been often ascribed to confounding effects of long duration of illness and chronic treatment with psychotropic medications of the subjects studied (chronic psychosis). In the last years, several studies have focused on the study of subjects at their first episode of psychosis to overcome these possible confounders. The aim of this paper was to review the literature investigating HPA axis activity in first episode psychosis. Findings from these studies support the presence of HPA axis hyperactivity and a blunted HPA axis response to stress at the onset of psychosis. Possible biological pathways linking these HPA axis abnormalities to the development of psychosis are discussed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23369532     DOI: 10.1016/j.psyneuen.2012.12.025

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  47 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

2.  Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care.

Authors:  Shamima Saloojee; Jonathan K Burns; Ayesha A Motala
Journal:  Early Interv Psychiatry       Date:  2017-04-12       Impact factor: 2.732

3.  Hair cortisol in the perinatal period mediates associations between maternal adversity and disrupted maternal interaction in early infancy.

Authors:  Maja Nyström-Hansen; Marianne S Andersen; Jennifer E Khoury; Kirstine Davidsen; Andrew Gumley; Karlen Lyons-Ruth; Angus MacBeth; Susanne Harder
Journal:  Dev Psychobiol       Date:  2019-02-12       Impact factor: 3.038

4.  Cortisol Reactivity to Stress and Its Association With White Matter Integrity in Adults With Schizophrenia.

Authors:  Katie L Nugent; Joshua Chiappelli; Hemalatha Sampath; Laura M Rowland; Kavita Thangavelu; Beshaun Davis; Xiaoming Du; Florian Muellerklein; Stacey Daughters; Peter Kochunov; L Elliot Hong
Journal:  Psychosom Med       Date:  2015-09       Impact factor: 4.312

5.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

6.  Hair cortisol as a marker of hypothalamic-pituitary-adrenal Axis activity in female patients with major depressive disorder.

Authors:  Ksenia Pochigaeva; Tatiana Druzhkova; Alexander Yakovlev; Mikhail Onufriev; Maria Grishkina; Aleksey Chepelev; Alla Guekht; Natalia Gulyaeva
Journal:  Metab Brain Dis       Date:  2017-01-07       Impact factor: 3.584

7.  From stress to psychosis: whom, how, when and why?

Authors:  V Mondelli
Journal:  Epidemiol Psychiatr Sci       Date:  2014-06-06       Impact factor: 6.892

8.  Stress Sensitivity and Psychotic Experiences in 39 Low- and Middle-Income Countries.

Authors:  Jordan E DeVylder; Ai Koyanagi; Jay Unick; Hans Oh; Boyoung Nam; Andrew Stickley
Journal:  Schizophr Bull       Date:  2016-04-24       Impact factor: 9.306

9.  Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load.

Authors:  Katie L Nugent; Joshua Chiappelli; Laura M Rowland; L Elliot Hong
Journal:  Psychoneuroendocrinology       Date:  2015-06-21       Impact factor: 4.905

10.  Migration, ethnicity and psychoses: evidence, models and future directions.

Authors:  Craig Morgan; Gemma Knowles; Gerard Hutchinson
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.